FrancophonIA/ELRC3.0 huggingface dataset:
English: Common Dyspnoea*, Cough*, Hiccups Uncommon Acute respiratory distress syndrome, Pulmonary embolism, Pneumonitis, Pulmonary hypertension, Pulmonary oedema (inc acute)
Croatian: Manje često Akutni respiratorni distres sindrom, plućna embolija, pneumonitis, plućna hipertenzija, plućni edem (uključujući akutni)
English: - Platelet counts should be ≥ 100,000 cells/μl and the absolute neutrophils count (ANC) should be ≥ 1,500 cells/μl
Croatian: - Broj trombocita mora biti ≥ 100 000 stanica/μl i apsolutni broj neutrofila mora biti ≥ 1500 stanica/μl - Broj trombocita mora biti ≥ 75 000 stanica/μl u bolesnika s infiltracijom koštane srži i sa sekvestracijom u slezeni - Hemoglobin ≥ 8 g/dl - Nehematološke toksičnosti moraju se povući na 1. stupanj ili početno stanje.
English: Incidence Adverse reaction Hepatobiliary disorders Common Hepatic enzyme abnormality* Uncommon Hepatotoxicity (inc liver disorder), Hepatitis*, Cholestasis
Croatian: Manje često Hepatotoksičnost (uključujući poremećaj jetre), hepatitis*, kolestaza
English: (95% CI) Hazard ratio (95% CI)c p-valued
Croatian: (95 % CI) p-vrijednostc
English: Refer to the Summary of Product Characteristics of rituximab for more information.
Croatian: Za više informacija pogledajte Sažetak opisa svojstava lijeka za rituksimab.
English: Dexamethasone 40 mg is given orally on days-1, 2, 3, 4, 8, 9, 10 and 11 of the Bortezomib SUN 28-day treatment cycle.
Croatian: Deksametazon od 40 mg primjenjuje se kroz usta 1., 2., 3., 4., 8., 9., 10. i 11. dan tijekom ciklusa liječenja Bortezomib SUN-om od 28 dana.
English: Haematological toxicity - ≥ Grade 3 neutropenia with fever, Grade 4 neutropenia lasting more than 7 days, a platelet count < 10,000 cells/μl
Croatian: Hematološka toksičnost - neutropenija ≥ stupnja 3 s vrućicom,
English: Bortezomib SUN is used for the treatment of: - multiple myeloma (a cancer of the bone marrow) in patients older than 18 years: alone or together with the medicines pegylated liposomal doxorubicin or dexamethasone, for patients whose disease is worsening (progressive) after receiving at least one prior treatment and for whom blood stem cell transplantation was not successful or is unsuitable.
Croatian: Bortezomib SUN primjenjuje se u liječenju: - multiplog mijeloma (rak koštane srži) u bolesnika starijih od 18 godina: samostalno ili zajedno sa lijekom pegiliranim liposomalnim doksorubicinom ili deksametazonom, u bolesnika kod kojih je došlo do pogoršanja bolesti (progresije) nakon posljednje terapije te su prethodno prošli ili nisu predviđeni za transplantaciju krvotvornih matičnih stanica. zajedno s lijekovima melfalan i prednizon u bolesnika koji prethodno nisu bili liječeni te nisu predviđeni za liječenje visokim dozama kemoterapije u kombinaciji s transplantacijom krvotvornih matičnih stanica. zajedno s lijekom deksametazonom ili deksametazonom zajedno s talidomidom za bolesnike koji prethodno nisu bili liječeni, te prije nego što prime liječenje visokim dozama kemoterapije u kombinaciji s transplantacijom matičnih krvotvornih stanica (uvodno liječenje). - limfoma plaštenih stanica(vrsta raka koji zahvaća limfne čvorove) u bolesnika starosti 18 godina ili starijih u kombinaciji s lijekovima rituksimabom, ciklofosfamidom, doksorubicinom i prednizonom, u bolesnika čija bolest prethodno nije bila liječena i za koje nije prikladna transplantacija krvnih matičnih stanica.
English: 4.2 mo
Croatian: 4,2 mjeseci
English: Uncommon side effects (may affect up to 1 in 100 people) - heart failure, heart attack, chest pain, chest discomfort, increased or reduced heart rate - failing of your kidneys - inflammation of a vein, blood clots in your veins and lungs - problems with blood clotting - insufficient circulation - inflammation of the lining around your heart or fluid around your heart - infections including urinary tract infections, the flu, herpes virus infections, ear infection and cellulitis - bloody stools, or bleeding from mucosal membranes, e.g., mouth, vagina - cerebrovascular disorders - paralysis, seizures, falling, movement disorders, abnormal or change in, or reduced sensation
Croatian: - infekcije, uključujući infekcije mokraćnih putova, gripa, infekcije virusom herpesa, infekcija uha i celulitis - krvave stolice ili krvarenje iz sluznica, npr. iz usta, rodnice - moždano-krvožilni poremećaji - paraliza, napadaji, padovi, poremećaji pokreta, abnormalnost ili promjena u, ili smanjen osjet
English: Then, Bortezomib SUN may be reinitiated with one dose level reduction (from 1.3 mg/m2 to 1 mg/m2, or from 1 mg/m2 to 0.7 mg/m2).
Croatian: može ponovno uvesti u dozi smanjenoj za jednu razinu doze (s 1,3 mg/m2 na 1 mg/m2, ili s 1 mg/m2 na 0,7 mg/m2).
English: Progression free survival (IRC)a Events n (%)
Croatian: n: ITT bolesnici Preživljavanje bez progresije (IRC)a
English: Progression-free survival Events n (%)
Croatian: Događaji n (%)
English: Common side effects (may affect up to 1 in 10 people) - low blood pressure, sudden fall of blood pressure on standing which may lead to fainting - high blood pressure - reduced functioning of your kidneys - headache - general ill feeling, pain, vertigo, light-headedness, a feeling of weakness or loss of consciousness - shivering - infections, including pneumonia, respiratory infections, bronchitis, fungal infections, coughing with phlegm, flu like illness - shingles (localised including around the eyes or spread across the body) - chest pains or shortness of breath with exercise - different types of rash - itching of the skin, lumps on the skin or dry skin - facial blushing or tiny broken capillaries - redness of the skin - dehydration - heartburn, bloating, belching, wind, stomach pain, bleeding from your bowels or stomach - alteration of liver functioning - a sore mouth or lip, dry mouth, mouth ulcers or throat pain - weight loss, loss of taste - muscle cramps, muscle spasms, muscle weakness, pain in your limbs - blurred vision - infection of the outermost layer of the eye and the inner surface of the eyelids (conjunctivitis) - nose bleeds - difficulty or problems in sleeping, sweating, anxiety, mood swings, depressed mood,
Croatian: - rane na ustima ili na usnama, suha usta, čirevi u ustima ili grlobolja - gubitak tjelesne težine, gubitak osjeta okusa - grčevi u mišićima, mišićni spazam, mišićna slabost, bol u udovima - zamućen vid - infekcija vanjskog sloja oka i unutarnje površine kapaka (konjunktivitis) - krvarenje iz nosa - poremećaji ili problemi sa spavanjem, znojenje, tjeskoba, promjene raspoloženja, depresivno raspoloženje, nemir i uznemirenost, promjene duševnog stanja, dezorijentiranost - oticanje tijela, uključujući područje oko očiju i druge dijelove tijela.
English: visual loss or disturbances and shortness of breath - memory loss, trouble thinking, difficulty with walking or loss of vision.
Croatian: nesvjestica - kašalj i poteškoće s disanjem ili stezanje u prsnom košu.
English: Description of selected adverse reactions
Croatian: Opis odabranih nuspojava Reaktivacija virusa herpes zoster
English: Hypermagnesaemia*, Acidosis, Electrolyte imbalance*,
Croatian: leukocitoza*, limfadenopatija, hemolitička anemija#
English: The areas harmonised include:
Croatian: Područja koja se moraju uskladiti obuhvaćaju:
English: What is Cymevene?
Croatian: Što je Cymevene?
English: The company that markets these medicines is F. Hoffmann - La Roche Ltd. and associated companies.
Croatian: Tvrtka koja te lijekove stavlja na tržište jest F. Hoffmann - La Roche Ltd. i povezane tvrtke.
English: It can infect almost anyone but usually remains dormant in healthy people, rarely causing symptoms.
Croatian: Može zaraziti gotovo bilo koga, ali obično ostaje u stanju mirovanja u zdravih ljudi, rijetko prouzročujući simptome.
English: Cymevene is marketed in all EU member states with the exception of Latvia, Malta and Slovenia.
Croatian: Cymevene se nalazi na tržištu svih država članica EU-a, osim u Latviji, Malti i Sloveniji.
English: The medicine can be used in adults and adolescents from 12 years of age.
Croatian: Lijek se može primjenjivati u odraslih i adolescenata starijih od 12 godina.
English: Cymevene has been authorised in the EU via national procedures.
Croatian: Cymevene je odobren u EU-u nacionalnim postupcima.
English: Information on the safety and efficacy of Cymevene in children under 12 years of age is limited.
Croatian: Informacije o sigurnosti i djelotvornosti lijeka Cymevene u djece mlađe od 12 godina su ograničene.
English: The CHMP was unable to make recommendations on such use based on currently available data and further assessment should be carried out.
Croatian: CHMP nije mogao dati preporuke o toj primjeni na temelju trenutačno dostupnih podataka te bi se trebale provesti daljnje procjene.
English: The European Commission issued an EU-wide legally binding decision on this opinion on 28 April 2016.
Croatian: Europska je komisija 28. travnja 2016 o tom mišljenju objavila odluku koja je pravno obvezujuća na području cijelog EU-a.
English: Why was Cymevene reviewed?
Croatian: Zašto je Cymevene ponovno ocjenjivan?
English: The Committee also harmonised other sections of the SmPC including sections 4.4 (special warnings and precautions for use), 4.5 (interactions) and 4.8 (side effects).
Croatian: Odbor je također uskladio druge dijelove sažetka opisa svojstava lijekova, uključujući i dijelove 4.4. (posebna upozorenja i mjere opreza pri uporabi), 4.5. (interakcije s drugim lijekovima i drugi oblici interakcija) i 4.8. (nuspojave).
English: In these patients, CMV can result in severe or life-threatening infections that attack various organs including the lungs, brain and eyes.
Croatian: U tih bolesnika CMV može rezultirati teškim ili po život opasnim infekcijama koje napadaju različite organe, uključujući pluća, mozak i oči.
English: It is also available in the EU under the names Cymevan, Cymeven i.v.
Croatian: U EU-u je također dostupan pod nazivima Cymevan, Cymeven i.v. i Citovirax.
English: On 25 February 2016, the European Medicines Agency completed a review of Cymevene.
Croatian: Europska agencija za lijekove 25. veljače 2016. dovršila je pregled lijeka Cymevene.
English: For this reason, the CHMP agreed that Cymevene should not be used in pregnant women unless the potential benefit to the mother outweighs the potential risk to the unborn child.
Croatian: Zbog toga se CHMP složio da se Cymevene ne smije upotrebljavati u trudnih žena osim ako moguća korist za majku nadmašuje mogući rizik za nerođeno dijete.
English: Patients with reduced kidney function should receive lower doses of Cymevene.
Croatian: Bolesnici sa smanjenom funkcijom bubrega trebali bi primati manje doze lijeka Cymevene.
English: Questions and answers on Cymevene and associated names (ganciclovir, 500 mg powder for concentrate for solution for infusion, intravenous)
Croatian: Pitanja i odgovori o lijeku Cymevene i povezanim nazivima (ganciklovir, prašak od 500 mg za koncentrat za otopinu za infuziju, intravensku)
English: Ganciclovir has the potential to cause birth defects in humans.
Croatian: Ganciklovir potencijalno može prouzročiti urođene mane u ljudi.
English: CMV is a common virus that belongs to the herpes virus family.
Croatian: CMV je uobičajeni virus koji se ubraja u porodicu herpes virusa.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the prescribing information for Cymevene in the European Union (EU).
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je da postoji potreba za usklađivanjem informacija za propisivanje lijeka Cymevene u Europskoj uniji (EU).
English: Since the use of highly active antiretroviral therapy (HAART) has reduced the risk of CMV disease in patients with HIV infection, preventive treatment with Cymevene is no longer considered necessary.
Croatian: S obzirom na to da se primjenom visokoaktivne antiretrovirusne terapije (HAART) smanjio rizik od bolesti prouzročene CMV-om u pacijenata s infekcijom HIV-om, preventivno liječenje lijekom Cymevene više se ne smatra potrebnim.
English: When prescribing Cymevene, consideration should be given to official guidance on the appropriate use of antiviral agents.
Croatian: Pri propisivanju lijeka Cymevene potrebno je uzeti u obzir službene smjernice o pravilnoj primjeni antivirusnih lijekova.
English: This has led to divergences across member states in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.
Croatian: To je dovelo do divergencije među državama članicama s obzirom na način primjene lijeka, što je vidljivo u razlikama među sažetcima opisa svojstava lijeka, označivanjima i uputama o lijeku u državama u kojima se lijek stavlja u promet.
English: Cymevene must not be used in patients allergic to its active substance ganciclovir, to a related antiviral medicine, valganciclovir, or to any other ingredients of the medicine.
Croatian: Cymevene se ne smije primjenjivati u bolesnika alergičnih na njegovu djelatnu tvar ganciklovir, na povezani antivirusni lijek valganciklovir, ili na bilo koji drugi sastojak lijeka.
English: Different treatment schedules should be followed during initial and maintenance treatment, in accordance with treatment guidelines.
Croatian: Tijekom početne terapije i terapije održavanja potrebni su različiti rasporedi liječenja, u skladu sa smjernicama liječenja.
English: However, the virus can cause problems in people with a weakened immune system such as people with acquired immune deficiency syndrome (AIDS) or who are undergoing cancer treatment or taking medicines to prevent rejection of an organ transplant.
Croatian: Međutim, virus može prouzročiti simptome u ljudi oslabljenog imunološkog sustava kao što su ljudi sa sindromom stečene imunodeficijencije (AIDS-om) ili koji se liječe od raka ili uzimaju lijekove za sprječavanje odbacivanja transplantiranih organa.
English: Having harmonised the indication, the CHMP also harmonised the recommendations on how to use Cymevene.
Croatian: Nakon usklađivanja indikacija CHMP je također uskladio preporuke o načinu primjene lijeka Cymevene.
English: Women who could become pregnant must be advised to use effective contraception during treatment with Cymevene and for at least 30 days after treatment has stopped.
Croatian: Žene koje bi mogle zatrudnjeti potrebno je savjetovati da se koriste učinkovitom kontracepcijom tijekom liječenja lijekom Cymevene te još barem 30 dana nakon prestanka liječenja.
English: On 15 September 2014, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Cymevene in the EU.
Croatian: Europska je komisija 15. rujna 2014. uputila predmet CHMP-u u cilju usklađivanja odobrenja za stavljanje u promet lijeka Cymevene u EU-u.
English: The recommended dose of Cymevene and duration of treatment depend on the weight of the patient and on whether the medicine is used to prevent or treat CMV disease.
Croatian: Preporučena doza lijeka Cymevene i trajanje liječenja ovise o tjelesnoj težini bolesnika te o tomu upotrebljava li se lijek za sprječavanje ili liječenje bolesti prouzročene CMV-om.
English: Cymevene is an antiviral medicine that is used to treat or prevent infection with cytomegalovirus (CMV) in immunocompromised individuals (people with a weakened immune system).
Croatian: Cymevene je antivirusni lijek koji se upotrebljava za liječenje ili sprječavanje infekcije citomegalovirusom (CMV-om) u imunokompromitiranih osoba (ljudi oslabljenog imunosnog sustava).
English: Men whose female partner could become pregnant must be advised to use barrier contraception methods during treatment with Cymevene, and for at least 90 days afterwards.
Croatian: Muškarce čija bi partnerica mogla zatrudnjeti potrebno je savjetovati da se koriste kontracepcijskim metodama barijere tijekom liječenja lijekom Cymevene te još barem 90 dana nakon prestanka liječenja.
English: Cymevene contains the active substance ganciclovir and is available as a powder to be made into a solution for infusion (drip) into a vein.
Croatian: Cymevene sadržava djelatnu tvar ganciklovir te je dostupan kao prašak od kojeg se priprema otopina za infuziju (drip) u venu.
English: Cymevene can also be used to prevent CMV disease in patients with drug-induced immunosuppression (for example after an organ transplant or chemotherapy).
Croatian: Lijek Cymevene također se može primjenjivati za sprječavanje bolesti prouzročene CMV-om u bolesnika s imunosupresijom izazvanom lijekovima (na primjer, nakon transplantacije organa ili kemoterapije).
English: The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.
Croatian: U svjetlu dostavljenih podataka i znanstvene rasprave unutar Odbora, mišljenje je CHMP-a da se sažetci opisa svojstava lijeka, označivanje i upute o lijeku moraju uskladiti na razini EU-a.
English: The CHMP also agreed that Cymevene should no longer be indicated for the prevention of CMV disease in patients with AIDS.
Croatian: CHMP se također složio da Cymevene više ne smije biti indiciran za sprječavanje bolesti prouzročene CMV-om u bolesnika s AIDS-om.
English: The CHMP agreed that Cymevene can be used for the treatment of diseases caused by CMV in immunocompromised patients.
Croatian: CHMP se složio da se lijek Cymevene može primjenjivati za liječenje bolesti prouzročenih CMV-om u imunokompromitiranih bolesnika.
English: Cymevene was identified as needing harmonisation by the Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh).
Croatian: Koordinacijska grupa za postupak međusobnog priznavanja i decentralizirani postupak za humane lijekove (CMDh) utvrdila je potrebu za usklađivanjem lijeka Cymevene.
English: It is not known whether ganciclovir passes into breast milk; however this possibility cannot be excluded and therefore breastfeeding must be discontinued in women treated with Cymevene, to avoid potential serious side effects in breastfed infants.
Croatian: Nije poznato izlučuje li se ganciklovir u majčino mlijeko, međutim ta se mogućnost ne može odbaciti.
English: ATCvet code: QI02AD04.
Croatian: ATCvet kod: QI02AD04.
English: NZ amine
Croatian: NZ amin
English: It is recommended to use a new applicator for each animal.
Croatian: Preporučuje se uporaba novog aplikatora za svaku životinju.
English: EXP {month/year} Once reconstituted use immediately.
Croatian: EXP {mjesec/godina} Jednom rekonstituiran odmah upotrijebiti.
English: Date of first authorisation: 29/07/2019
Croatian: Datum prvog odobrenja: 29/07/2019
English: The following doses and administration methods should be used:
Croatian: Treba koristiti sljedeće doze i metode primjene:
English: <{DD/MM/YYYY}>
Croatian: {DD/MM/GGGG}
English: The 5 doses vial is now ready to use.
Croatian: Bočica s 5 doza sada je spremna za korištenje.
English: Shake well before use.
Croatian: Dobro protresite prije uporabe.
English: Shelf life of the veterinary medicinal product as packaged for sale: 15 months.
Croatian: Rok valjanosti veterinarsko-medicinskog proizvoda kad je zapakiran za prodaju: 15 mjeseci.
English: *Cell culture infectious dose 50%
Croatian: * Infektivna doza kulture stanica 50%
English: One dose is 2 ml.
Croatian: Jedna doza je 2 ml.
English: Avoid contamination during reconstitution and use.
Croatian: Izbjegavajte onečišćenje tijekom pripreme i uporabe.
English: Solvent: Store below 25 °C.
Croatian: Otapalo: Čuvati pri temperaturi do 25 °C.
English: Overdose (symptoms, emergency procedures, antidotes): No adverse reactions occurred following the administration of an overdose.
Croatian: Predoziranje (simptomi, hitni postupci, antidoti): Nisu se pojavile nuspojave nakon primjene predoziranja.
English: Calves may uncommonly display a peak in temperature of at least 1.7°C two days after vaccination that resolves the next day without treatment.
Croatian: Goveda mogu manje često imati porast temperature od najmanje 1,7°C dva dana nakon cijepljenja koja prestaje sljedećeg dana bez liječenja.
English: Reduction of respiratory clinical signs (but not a reduction of virus shedding) is observed 5 days after nasal vaccination.
Croatian: Smanjenje respiratornih kliničkih znakova (ne i širenja virusa) uočeno je 5 dana nakon nazalne primjene.
English: Cattle from 9 days of age:
Croatian: Telad od 9. dana starosti:
English: The excipients listed in section 6.1 of the SPC are allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.
Croatian: Pomoćne tvari (uključujući adjuvanse), navedene u dijelu 6.1 SPC su ili dozvoljene tvari za koje je u tablici 1, Dodatka Uredbe Komisije (EU) br. 37/2010 navedeno da određivanje MRL nije nužno, ili se smatra da se na njih ne primjenjuju odredbe Uredbe (EK) br. 470/2009 kada se primjenjuju u tim veterinarsko-medicinskim proizvodima.
English: The reconstituted vaccine is a slightly yellowish homogeneous suspension.
Croatian: Rekonstituirano cjepivo je blago žućkasta homogena suspenzija.
English: Pharmacotherapeutic group: Immunological for Bovidae, Cattle, Live viral vaccines, bovine respiratory syncytial virus (BRSV).
Croatian: Farmakoterapijska grupa: Imunološki za bovidae, goveda, živa virusna cjepiva, goveđi respiratorni sincicijski virus (BRSV).
English: Volume of solvent to be used
Croatian: Volumen otapala koji se koristi
English: 6 months after intramuscular vaccination.
Croatian: 6 mjeseci nakon intramuskularnog cijepljenja.
English: Cattle from 10 weeks of age:
Croatian: Telad od 10. tjedna starosti:
English: Slight alteration of faecal consistency may be commonly observed post-vaccination.
Croatian: Blaga promjena fekalne konzistencije može se često primijetiti nakon cijepljenja.
English: Do not use this veterinary medicinal product and the solvent after the expiry date which is stated on the carton and the label.
Croatian: Ovaj veterinarsko-medicinski proizvod i otapalo nemojte koristiti nakon isteka roka valjanosti navedenog na kutiji i naljepnici.
English: For nasal use, spray the required volume of the vaccine into the animal's nostrils (1 ml in each nostril) using an intranasal applicator (droplet size: 25-220 µm).
Croatian: Za nazalnu primjenu, raspršite potrebnu količinu cjepiva u nosnicu životinje (1 ml u svaku nosnicu) pomoću intranazalnog aplikatora (veličina kapljica: 25-220 µm).
English: Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Croatian: Ne koristiti u slučaju preosjetljivosti na djelatnu tvar ili bilo koju pomoćnu tvar.
English: Lyophilisate: Store and transport refrigerated (2 °C - 8 °C).
Croatian: Liofilizat: Čuvati i prevoziti na hladnom (2 °C - 8 °C).
English: Use only sterile needles and syringes for administration.
Croatian: Za primjenu koristite samo sterilne igle i šprice.
English: Each dose of 2 ml contains: Lyophilisate:
Croatian: Svaka doza od 2 ml sadrži: Liofilizat:
English: Do not mix with any other veterinary medicinal product, except with the solvent supplied for use with the veterinary medicinal product.
Croatian: Nemojte miješati s drugim veterinarsko-medicinskim proizvodom, osim s otapalom isporučenim za uporabu s veterinarsko-medicinskim proizvodom.
English: No adverse reactions other than those described in section 4.6 occurred following the administration of an overdose.
Croatian: Nakon primjene predoziranja nisu se pojavile nuspojave osim onih opisanih u odjeljku 4.6.
English: Shake until the freeze-dried powder is in suspension.
Croatian: Tresite dok se smrznuti prašak ne suspendira.
English: Duration of immunity: 2 months after nasal vaccination.
Croatian: Trajanje imunosti: 2 mjeseca nakon nazalnog cijepljenja.
English: Active immunisation of cattle to reduce virus shedding and respiratory clinical signs caused by bovine respiratory syncytial virus infection.
Croatian: Aktivna imunizacija goveda radi smanjenja širenja virusa i respiratornih kliničkih znakova uzrokovanih infekcijom goveđim respiratornim sincicijskim virusom.